Analyses on activation of NF-κB and effect of bortezomib in canine neoplastic lymphoid cell lines

Journal of Veterinary Medical Science

Volumn 75, Issue 6, 2013, Pages 727-731

  Kojima, Ko ^a   Fujino, Yasuhito ^a   Goto Koshino, Yuko ^a   Ohno, Koichi ^a   Tsujimoto, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Canine; Leukemia; Lymphoma; Nuclear factor kappa B; Proteasome inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PYRAZINE DERIVATIVE;

ANIMAL; ARTICLE; DOG; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTE; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; LYMPHOCYTES; NF-KAPPA B; PYRAZINES;

CANIS FAMILIARIS;

EID: 84879598200     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.12-0168     Document Type: Article

References (21)

1. Adams, J. 2001. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 28: 613-619. [Medline] [CrossRef]
2. Davis, R. E., Brown, K. D., Siebenlist, U. and Staudt, L. M. 2001. Constitutive Nuclear Factor κB activity is required for survival of activated B cell-like diffuse large b cell lymphoma cells. J. Exp. Med. 194: 1861-1874. [Medline] [CrossRef]
3. Dunleavy, K., Pittaluga, S., Czuczman, M. S., Dave, S. S., Wright, G., Grant, N., Shovlin, M., Jaffe, E. S., Janik, J. E., Staudt, L. M. and Wilson, W. H. 2009. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113: 6069-6076. [Medline] [CrossRef]
4. Dyer, R. B. and Herzog, N. K. 1995. Isolation of intact nuclei for nuclear extract preparation from a fragile B-lymphocyte cell line. Biotechniques 19: 192-195. [Medline]
5. Fahy, B. N., Schlieman, M. G., Mortenson, M. M., Virudachalam, S. and Bold, R. J. 2005. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother. Pharmacol. 56: 46-54. [Medline] [CrossRef]
6. Friess, M., Engelhardt, P., Dobbelaere, D., Zurbriggen, A. and Gröne, A. 2005. Reduced nuclear translocation of Nuclear Factor (NF)-κB p65 in the footpad epidermis of dogs infected with distemper virus. J. Comp. Pathol. 132: 82-89. [Medline] [CrossRef]
7. Hassan, S. B., Haglund, C., Åleskog, A., Larsson, R. and Lindhagen, E. 2007. Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity. Toxicol. In Vitro 21: 1174-1181. [Medline] [CrossRef]
8. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J. and Anderson, K. C. 2001. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61: 3071-3076. [Medline]
9. Hiraoka, H., Minami, K., Kaneko, N., Shimokawa Miyama, T., Okamura, Y., Mizuno, T. and Okuda, M. 2009. Aberrations of the FHIT gene and Fhit protein in canine lymphoma cell lines. J. Vet. Med. Sci. 71: 769-777. [Medline] [CrossRef]
10. Liu, X., Wang, B., Ma, X. and Guo, Y. 2009. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type. Jpn. J. Clin. Oncol. 39: 418-424. [Medline] [Cross- Ref]
11. Ma, M. H., Yang, H. H., Parker, K., Manyak, S., Friedman, J. M., Altamirano, C., Wu, Z. Q., Borad, M. J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R. A. and Berenson, J. R. 2003. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9: 1136-1144. [Medline]
12. Matsuda, A., Tanaka, A., Muto, S., Ohmori, K., Furusaka, T., Jung, K., Karasawa, K., Okamoto, N., Oida, K., Itai, A. and Matsuda, H. 2010. A novel NF-κB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors. Res. Vet. Sci. 89: 378-382. [Medline] [CrossRef]
13. Matta, H. and Chaudhary, P. M. 2005. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol. Ther. 4: 77-82. [Medline] [CrossRef]
14. Momoi, Y., Okai, Y., Watari, T., Goitsuka, R., Tsujimoto, H. and Hasegawa, A. 1997. Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma. Vet. Immunol. Immunopathol. 59: 11-20. [Medline] [CrossRef]
15. Nakaichi, M., Taura, Y., Kanki, M., Mamba, K., Momoi, Y., Tsujimoto, H. and Nakama, S. 1996. Establishment and characterization of a new canine B-cell leukemia cell line. J. Vet. Med. Sci. 58: 469-471. [Medline] [CrossRef]
16. Packham, G. 2008. The role of NF-kB in lymphoid malignancies. Br. J. Haematol. 143: 3-15. [Medline] [CrossRef]
17. Rütgen, B. C., Hammer, S. E., Gerner, W., Christian, M., de Arespacochaga, A. G., Willmann, M., Kleiter, M., Schwendenwein, I. and Saalmüller, A. 2010. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk. Res. 34: 932-938. [Medline] [CrossRef]
18. Sors, A., Jean-Louis, F., Pellet, C., Laroche, L., Dubertret, L., Courtois, G., Bachelez, H. and Michel, L. 2006. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107: 2354-2363. [Medline] [CrossRef]
19. Vallabhapurapu, S. and Karin, M. 2009. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 27: 693-733. [Medline] [CrossRef]
20. Yamazaki, J., Baba, K., Goto-Koshino, Y., Setoguchi-Mukai, A., Fujino, Y., Ohno, K. and Tsujimoto, H. 2008. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction. Vet. Immunol. Immunopathol. 126: 321-331. [Medline] [CrossRef]
21. Yu, X., Huang, S., Patterson, E., Garrett, M. W., Kaufman, K. M., Metcalf, J. P., Zhu, M., Dunn, S. T. and Kem, D. C. 2005. Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 289: H1960-H1967. [Medline] [CrossRef]